Aviesan/Ariis model collaboration agreements

In order to encourage and spur the signing of collaboration agreements, Aviesan (French National Alliance for Life Sciences and Health) and Ariis (Alliance for Research and Innovation in Health Industries) have prepared model collaboration agreements

These models form a basis for legal negotiation to support the establishment of public-private partnerships. They enable points of consensus to be dealt with as quickly as possible, allowing the lawyers to concentrate on the essential elements of the negotiation, and should be adapted to suit the situation.

There are four of these models, designed to accommodate different partnership situations as described below. There is a user guide to complement each model and provide further detail on some specific items.

 

 

Model 1

The initiative comes essentially from the academic party, which carries out the main part of the research work. The research component is not essential for the industrial party. The totality of the results is the property of the academic party. For the industry, the interest lies in having access to the results of the project, and, if it wishes, in having the right to exploit them.
E.g.: To validate its technology, the academic needs a diagnostic kit, instrument, etc., belonging to the industry. For the industrial party, it is an opportunity to evaluate this technology and gain better knowledge of it.

Download Model Collaboration Contract 1 (2014) (132.9 ko)

 

Model 2

Both parties are similarly motivated. Ownership of results is divided into different “results packages” (and not into work packages). The definition of results packages is a function of prior knowledge and of the strategic elements of each. Ownership of results is assigned regardless of the level of participation of each party in the achievement of these results. However, joint ownership remains possible for certain packages.
E.g.: The academic party supplies research tools (animal models of diseases). The industrial party uses these models to evaluate therapeutic drugs that it owns. The industry will be the owner of all results needed for the use of the drug, and the academic party will be the owner of all results that allow exploitation of the research tools.

Download Model Collaboration Contract 2 (2014) (114.8 ko)

 

Model 3

Both parties are similarly motivated. Joint ownership is assigned in equal shares or in accordance with the contribution of each to obtaining the results. The protection and exploitation of the results relies on the definition of territories and fields.
E.g.: Joint development of a tool that is applicable to different diseases (cancer, diabetes: fields), with each party reserving the right to exploit it by field of interest in a territory.

Download Model Collaboration Contract 3 (2014) (113.5 ko)

 

Model 4

The initiative comes essentially from the industrial party, for which the research component appears strategic. The industry is the owner of the totality of results. For the academic party, the interest lies in accessing funding for its research and in acquiring new knowledge on one of its technologies. This type of agreement differs from a service, particularly by the fact that it does not involve only the application of proven technologies.
E.g.: A study of drugs owned by the industrial party, which involves a technology owned by the academic party, but not involving the application of proven technologies.

Download Model Collaboration Contract 4 (2014) (111.4 ko)

 

These models have been approved by the Presidents of Ariis and Aviesan, and by:

If you have a suggestion, comment or question, do not hesitate to contact us: covalliance@aviesan.fr

View Edit Create here